Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial

PURPOSE: A phase II, open-label, dose-finding, randomized study was performed to evaluate the recommended dose of pegfilgrastim in Japanese breast cancer patients. METHODS: Patients received 1.8, 3.6, or 6.0 mg of pegfilgrastim once per chemotherapy cycle for up to 6 cycles. Patients received doceta...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Norikazu, Tokuda, Yutaka, Nakamura, Seigo, Shimazaki, Ryutaro, Ito, Yoshinori, Tamura, Kazuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552775/
https://www.ncbi.nlm.nih.gov/pubmed/25733000
http://dx.doi.org/10.1007/s00520-015-2654-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552775/
https://www.ncbi.nlm.nih.gov/pubmed/25733000
http://dx.doi.org/10.1007/s00520-015-2654-4

Ejemplares similares